NYSEAMERICAN:ATNM Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News $5.92 -0.24 (-3.90%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$5.90▼$6.1550-Day Range$7.12▼$14.2652-Week Range$5.87▼$15.12Volume222,000 shsAverage Volume279,743 shsMarket Capitalization$159.84 millionP/E RatioN/ADividend YieldN/APrice Target$28.32 ProfileProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesOptions ChainShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesOptions ChainShort InterestSocial Media Actinium Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside378.4% Upside$28.32 Price TargetShort InterestBearish7.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.05) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 stars 3.4 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.32, Actinium Pharmaceuticals has a forecasted upside of 378.4% from its current price of $5.92.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.22% of the outstanding shares of Actinium Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverActinium Pharmaceuticals has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Actinium Pharmaceuticals has recently decreased by 5.34%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 1.8 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.38% of the stock of Actinium Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) StockActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.Read More ATNM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingSeptember 23, 2023 | finance.yahoo.comActinium to Host Key Opinion Leader Event Focused on Bone Marrow Transplant, Potential Role of Iomab-B on May 12October 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 15, 2023 | msn.comActinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?September 10, 2023 | msn.comHSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on GileadSeptember 7, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Inovio Pharmaceuticals (INO)September 7, 2023 | finance.yahoo.comActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOSeptember 7, 2023 | msn.comHSBC Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Buy RecommendationOctober 2, 2023 | Behind the Markets (Ad)3 Words and a 3,000% ReturnIn October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>September 1, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)August 31, 2023 | finance.yahoo.comActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAugust 21, 2023 | finance.yahoo.comActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressAugust 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)August 15, 2023 | msn.comHC Wainwright & Co. Maintains Actinium Pharmaceuticals (ATNM) Buy RecommendationJuly 24, 2023 | finance.yahoo.comActinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals SummitJune 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Cognition Therapeutics (CGTX)June 26, 2023 | finance.yahoo.comSNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA DataJune 23, 2023 | finance.yahoo.comActinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual MeetingJune 16, 2023 | finance.yahoo.comActinium Pharma to Present at the Maxim Healthcare Virtual ConferenceJune 12, 2023 | finance.yahoo.comActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 CongressJune 7, 2023 | finance.yahoo.comActinium Pharma Set to Join Russell 2000® and Russell 3000® IndexesMay 22, 2023 | finance.yahoo.comActinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid CancersMay 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), Sutro Biopharma (STRO) and Karuna Therapeutics (KRTX)May 13, 2023 | forbes.comCatalyst PharmaceuticalsMay 11, 2023 | finance.yahoo.comActinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)April 28, 2023 | finance.yahoo.comActinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) CongressApril 27, 2023 | finance.yahoo.comActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual MeetingSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNM Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.32 High Stock Price Forecast$50.00 Low Stock Price Forecast$11.60 Forecasted Upside/Downside+378.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,020,000.00 Net MarginsN/A Pretax Margin-102,975.55% Return on Equity-74.73% Return on Assets-42.90% Debt Debt-to-Equity RatioN/A Current Ratio10.44 Quick Ratio10.44 Sales & Book Value Annual Sales$1.03 million Price / Sales155.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book2.27Miscellaneous Outstanding Shares27,000,000Free Float25,999,000Market Cap$159.84 million OptionableOptionable Beta0.38 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Sandesh C. Seth M.B.A. (Age 59)M.S., MBA, Chairman & CEO Comp: $1.15MMr. Steven O'Loughlin BS (Age 37)CFO & Corp. Sec. Comp: $585kDr. Paul Diamond Esq.Ph.D., VP of Patent & Legal CounselDr. David GouldSr. VP of Corp. Devel. & Corp. AffairsDr. Bernie Cunningham P.M.P.Ph.D., Exec. Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing LiangVP & Head of Radiation SciencesDr. Avinash Desai M.D.Chief Medical OfficerMs. Jenny HsiehChief Strategy OfficerMs. Sunitha LakshminarayananSr. VP, Head of CMC & Product Devel.Ms. Elaina HaeuberVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsCytoDynOTCMKTS:CYDYAtara BiotherapeuticsNASDAQ:ATRAAlpha Tau MedicalNASDAQ:DRTSPardes BiosciencesNASDAQ:PRDSParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInstitutional OwnershipBarclays PLCSold 50,477 shares on 9/21/2023Ownership: 0.019%California State Teachers Retirement SystemBought 8,653 shares on 8/21/2023Ownership: 0.032%Nuveen Asset Management LLCBought 99,346 shares on 8/16/2023Ownership: 0.368%Citadel Advisors LLCSold 5,100 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 1,871 shares on 8/15/2023Ownership: 0.026%View All Institutional Transactions ATNM Stock - Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks. What is Actinium Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month target prices for Actinium Pharmaceuticals' shares. Their ATNM share price forecasts range from $11.60 to $50.00. On average, they predict the company's share price to reach $28.32 in the next year. This suggests a possible upside of 378.4% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts. How have ATNM shares performed in 2023? Actinium Pharmaceuticals' stock was trading at $10.65 on January 1st, 2023. Since then, ATNM stock has decreased by 44.4% and is now trading at $5.92. View the best growth stocks for 2023 here. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 1,950,000 shares, a decline of 5.3% from the August 31st total of 2,060,000 shares. Based on an average trading volume of 166,400 shares, the short-interest ratio is currently 11.7 days. View Actinium Pharmaceuticals' Short Interest. When is Actinium Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ATNM earnings forecast. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.08. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). What is Actinium Pharmaceuticals' stock symbol? Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM." How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Actinium Pharmaceuticals' stock price today? One share of ATNM stock can currently be purchased for approximately $5.92. How much money does Actinium Pharmaceuticals make? Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $159.84 million and generates $1.03 million in revenue each year. The biotechnology company earns $-33,020,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. How can I contact Actinium Pharmaceuticals? Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com. This page (NYSEAMERICAN:ATNM) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.